These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 26678617)

  • 1. Optimized Peptide Amount and Activity for ⁹⁰Y-Labeled DOTATATE Therapy.
    Kletting P; Kull T; Maaß C; Malik N; Luster M; Beer AJ; Glatting G
    J Nucl Med; 2016 Apr; 57(4):503-8. PubMed ID: 26678617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in
    Jiménez-Franco LD; Glatting G; Prasad V; Weber WA; Beer AJ; Kletting P
    J Nucl Med; 2021 Jan; 62(1):92-98. PubMed ID: 32646878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of time-integrated activity coefficients in PRRT using simulated dynamic PET and a pharmacokinetic model.
    Hardiansyah D; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Phys Med; 2017 Oct; 42():298-304. PubMed ID: 28739143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for 177Lu-Labeled PSMA-Targeting Peptides.
    Kletting P; Schuchardt C; Kulkarni HR; Shahinfar M; Singh A; Glatting G; Baum RP; Beer AJ
    PLoS One; 2016; 11(9):e0162303. PubMed ID: 27611841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of patient-based treatment planning in peptide receptor radionuclide therapy.
    Hardiansyah D; Maass C; Attarwala AA; Müller B; Kletting P; Mottaghy FM; Glatting G
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):871-880. PubMed ID: 26577941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment planning in PRRT based on simulated PET data and a PBPK model. Determination of accuracy using a PET noise model.
    Hardiansyah D; Guo W; Attarwala AA; Kletting P; Mottaghy FM; Glatting G
    Nuklearmedizin; 2017 Feb; 56(1):23-30. PubMed ID: 27885372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
    Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
    Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
    Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
    J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?
    Esser JP; Krenning EP; Teunissen JJ; Kooij PP; van Gameren AL; Bakker WH; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2006 Nov; 33(11):1346-51. PubMed ID: 16847654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of 90Y-DOTATATE therapy in neuroendocrine tumours.
    Sowa-Staszczak A; Pach D; Kunikowska J; Krolicki L; Stefanska A; Tomaszuk M; Buziak-Bereza M; Mikolajczak R; Matyja M; Gilis-Januszewska A; Jabrocka-Hybel A; Trofimiuk M; Hubalewska-Dydejczyk A
    Endokrynol Pol; 2011; 62(5):392-400. PubMed ID: 22069099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
    Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
    J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
    Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
    Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function affects absorbed dose to the kidneys and haematological toxicity during ¹⁷⁷Lu-DOTATATE treatment.
    Svensson J; Berg G; Wängberg B; Larsson M; Forssell-Aronsson E; Bernhardt P
    Eur J Nucl Med Mol Imaging; 2015 May; 42(6):947-55. PubMed ID: 25655484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function.
    Ranade R; Basu S
    J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High clinical and morphologic response using
    Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feasibility and utility of re-treatment with (177)Lu-DOTATATE in GEP-NENs relapsed after treatment with (90)Y-DOTATOC.
    Severi S; Sansovini M; Ianniello A; Bodei L; Nicolini S; Ibrahim T; Di Iorio V; D'Errico V; Caroli P; Monti M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2015 Dec; 42(13):1955-63. PubMed ID: 26112388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTATATE: the IEO phase I-II study.
    Bodei L; Cremonesi M; Grana CM; Fazio N; Iodice S; Baio SM; Bartolomei M; Lombardo D; Ferrari ME; Sansovini M; Chinol M; Paganelli G
    Eur J Nucl Med Mol Imaging; 2011 Dec; 38(12):2125-35. PubMed ID: 21892623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution, Pharmacokinetics, and Dosimetry of
    Nicolas GP; Mansi R; McDougall L; Kaufmann J; Bouterfa H; Wild D; Fani M
    J Nucl Med; 2017 Sep; 58(9):1435-1441. PubMed ID: 28450554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.